GUT BARRIER & INFLAMMATION RESET

• BPC-157 (Oral) : The “Body Protection Compound.” When taken orally (especially as a stable salt like Arginate), it survives gastric acid to heal the stomach lining, esophagus, and intestinal mucosa locally.

• KPV (Oral): The anti-inflammatory fragment of $alpha$-MSH. Oral delivery is often used here to treat intestinal candidiasis (yeast) and calm inflammation in the colon (Colitis/IBD).

• Larazotide (AT-1001) : A peptide specifically engineered to act as a Zonulin Antagonist. Zonulin is the protein that triggers “tight junctions” in the gut to open (causing leaky gut). Larazotide helps lock these junctions closed. It has been in Phase 3 clinical trials for Celiac disease.

• LL-37 1 Unit: The antimicrobial peptide. Included here likely to “scrub” the gut of pathogenic bacteria or biofilms (dysbiosis).

Protocol mechanism:

• BPC-157 (Oral): The “Body Protection Compound.” When taken orally (especially as a stable salt like Arginate), it survives gastric acid to heal the stomach lining, esophagus, and intestinal mucosa locally.

• KPV (Oral): The anti-inflammatory fragment of $alpha$-MSH. Oral delivery is often used here to treat intestinal candidiasis (yeast) and calm inflammation in the colon (Colitis/IBD).

• Larazotide (AT-1001): A peptide specifically engineered to act as a Zonulin Antagonist. Zonulin is the protein that triggers “tight junctions” in the gut to open (causing leaky gut). Larazotide helps lock these junctions closed. It has been in Phase 3 clinical trials for Celiac disease.
• LL-37: The antimicrobial peptide. Included here likely to “scrub” the gut of pathogenic bacteria or biofilms (dysbiosis).